WO2015110977A1 - Fatty acid composition and medicinal use thereof - Google Patents
Fatty acid composition and medicinal use thereof Download PDFInfo
- Publication number
- WO2015110977A1 WO2015110977A1 PCT/IB2015/050484 IB2015050484W WO2015110977A1 WO 2015110977 A1 WO2015110977 A1 WO 2015110977A1 IB 2015050484 W IB2015050484 W IB 2015050484W WO 2015110977 A1 WO2015110977 A1 WO 2015110977A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- composition
- mol
- fatty acid
- fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Definitions
- the fatty acids may be reptilian in origin.
- the reptiles from which the fatty acids may be obtained may be from the family Crocodylidae and/or or Alligatoridae.
- Test compounds were dissolved in DMSO and the final concentration in the wells was 2 % v/v.
- the positive controls were neomycin (S. aureus and K.pneumoniae) and amphotericin B ⁇ C.albicans) and the final concentrations in the wells were 100 ⁇ .
- Crocodile oil was tested at final concentrations in the wells of 0, 5, 6, 7, 8, 10 and 15 % (w/v).
- Individual fatty acids (pentadecanoic acid, oleic acid, palmitic acid and linoleic acid acid) were tested at final concentrations in the wells of 0.0028, 0.0049, 0.038, 0.049, 0.38 and 0.49 M.
- Diclofenac (0.07 mg; 3 hours) and fatty acids (0.23 mg pentadecanoic acid; 0.081 mg palmitic acid; 0.1 1 1 mg oleic acid and 0.0225 mg linoleic acid) in combination with quercetin (0.5 mg) was topically administered in 50 ⁇ acetone and the mice treated for 3 to 6 hours.
- the combination of fatty acids corresponds with the ratio in which they were naturally found in the Nile crocodile oil.
- Acetone as a vehicle has not been documented to have an anti-inflammatory effect on its own.
- Mice were euthanized in a CO2 chamber after treatment for 3 to 6 hours. From each mouse, left and right auricle biopsy specimens were obtained with a 6 mm biopsy punch and then weighed on an analytical balance.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides for a fatty acid composition, wherein the composition includes the constituent fatty acids, pentadecanoic acid, oleic acid, palmitic acid and linoleic acid in a ration other than what is commonly found in nature.
Description
Fatty Acid Composition and Medicinal Use Thereof
Background to the invention
Fatty acids play a vital role in the biosynthesis of hormone-like substances such as prostaglandins which regulate many body functions, including heart rate, blood pressure, blood clotting, fertility and conception. Individual fatty acids are known to have some antimicrobial activity, however, insufficient to be used in a medicinal composition. The inventors have thus identified the need to investigate fatty acid combinations which together would have a synergistic antimicrobial effect as opposed to any one of the fatty acids individually as an antimicrobial preparation Likewise, individual fatty acids are known to have some anti-inflammatory activity, however, insufficient to be used in a medicinal composition. The inventors have thus identified the need to investigate fatty acid combinations which together would have a synergistic antiinflammatory effect as opposed to any one of the fatty acids used individually as an antiinflammatory preparation.
Yet further, a need was identified to find a potentiator and/or enhancement reagent for the fatty acid composition.
It is with this need in mind that the inventors thus propose the following invention.
Summary of the Invention
According to a first aspect of the invention, there is provided a fatty acid composition , wherein the composition includes the constituent fatty acids, pentadecanoic acid, oleic acid, palmitic acid and linoleic acid in a ratio other than what is commonly found in nature.
It is to be appreciated from the specification that the pentadecanoic acid, oleic acid, palmitic acid and linoleic acid constituents are all classified as fatty acids and may be saturated or unsaturated fatty acids.
A constituent amount of pentadecanoic acid of greater than 25 mol% may have an increased antimicrobial effect.
The constituent amount of the pentadecanoic acid in the composition may range from 25 mol% to 66 mol%. Typically, the constituent amount of the pentadecanoic acid in the composition may range from 30 mol% to 55 mol%,
The constituent amount of the linoleic acid in the composition may range from 1 mol% to 10 mol% of the composition. Typically, the constituent amount of the linoleic acid in the composition may range from 3 mol% to 7 mol%.
The constituent amount of the oleic acid in the composition may range from 10 mol% to 40 mol%. Typically, the constituent amount of the oleic acid in the composition may range from 16 mol% to 30 mol%.
The constituent amount of the palmitic acid in the composition may range from 12 mol% to 36 mol%. Typically, the constituent amount of the palmitic acid in the composition may range from 16 mol% to 25 mol%. In a desired embodiment of the invention, the constituent amounts of the pentadecanoic acid may be 46 mol%, the linoleic acid may be 4.5 mol%, the oleic may be 22 mol% and the palmitic acid may be 18 mol%.
In another embodiment of the invention, the constituent amount of the palmitic acid in the composition may be less than the constituent amount of the oleic acid in the composition.
In yet another embodiment of the invention, the constituent amount of the linoleic acid in the composition may be lower than the constituent amounts of any one of the other three constituents.
In a further embodiment of the invention, the constituent amount of the pentadecanoic acid may be the highest constituent amount in the composition.
The constituents of the composition may be derived from nature or may be synthetic.
The fatty acids, if derived from nature, may be reptilian in origin.
The reptiles from which the fatty acids may be obtained may be from the family Crocodylidae and/or or Alligatoridae.
Thus, in an embodiment of the invention, the ratio of pentadecanoic acid: oleic acid: palmitic acid: linoleic acid may be 12:5:4:1 .
According to another aspect of the invention, there is provided the use of a fatty acid composition including at least pentadecanoic acid, oleic acid, palmitic acid and linoleic acid acids substantially as described above, as an antimicrobial medicament
According to yet another aspect of the invention, there is provided the use of a fatty acid composition including at least pentadecanoic acid, oleic acid, palmitic acid and linoleic acid acids substantially as described above, in the preparation of an inflammatory medicament According to a further aspect of the invention, there is provided an anti-inflammatory composition including at least pentadecanoic acid, oleic acid, palmitic acid, linoleic acid acids and a flavonoid-type substance.
The flavonoid-type substance may be quercetin, an analogue or an equivalent thereof.
The ratio of the flavonoid-type substance to the total of the fatty acid constituent may be greater than 1 :1 .
Thus, in an example, the quercetin to fatty acid ratio may be greater than 1 :1 , and may be as high as 2:1 and as low as 1 :2.
Description of an Example of the Invention
The invention will now be described, by way of non-limiting example only, with reference to the accompanying experimental work.
In the experimental work the relative ratios of the fatty acids and the quercetin are for illustrative purposes only and the scope of the invention is not intended to be limited to these or any specific ratio's.
1. Aim of the experimental Work
The aim of this project was to determine the fatty acid combination starting with the fatty acid content of a natural oil, such as a fat or oil from Alligator mississippiensis, Crocodylus siamensis, or the Nile crocodile, having anti-inflammatory and antimicrobial activities. In addition, a flavonoid-type substance (quercetin) was combined with the fatty acids to investigate a possible potentiating effect.
2. Methods
2.1 Antimicrobial susceptibility assays
2.1.1 Microbial strains
The following microorganisms were used (obtained from American Type Culture Collection - ATCC, Manassas, VA, USA):
• Staphylococcus aureus (ATCC strain 12600)
• Klebsiella pneumonia (ATCC strain 13883)
· Candida albicans (ATCC strain 10231 )
S.aureus and K.pneumoniae were cultured in Mueller-Hinton broth (optical density of 0.6-0.8 at 490 nm) and C.albicans (optical density of 0.3-0.5 at 630 nm) in Sabouraud dextrose broth. Broths were prepared according to the manufacturer's protocols.
2.1.2 Susceptibility tests
Tests were conducted in clear, sterile 96 well microtitre plates (Corning Life Sciences, Acton, MA, USA). The assay was based on the microplate method by Eloff (1998), but with modifications. Briefly, following steps were followed:
• A 100 μΙ well of appropriate broth was added.
• This was followed by a 100 μΙ well of the appropriate microbial culture.
• And finally by a 100 μΙ well of the appropriate test compound.
· The plate was incubated at 37eC for 18 {S.aureus and K.pneumoniae) or 24 hours {C.albicans).
• For S. aureus and K. pneumonia, 40 μΙ well of p-INT (400 μg/ml in water) was added and incubated (37eC; 15 minutes).
• Microbial growth was quantified by colourimetry (490 nm) for bacteria and optical density (690 nm) for C.albicans in a microplate reader (BioTek ELx800, Winooski,
VT, USA).
Test compounds were dissolved in DMSO and the final concentration in the wells was 2 % v/v. The positive controls were neomycin (S. aureus and K.pneumoniae) and amphotericin B {C.albicans) and the final concentrations in the wells were 100 μΜ. Crocodile oil was tested at final concentrations in the wells of 0, 5, 6, 7, 8, 10 and 15 % (w/v). Individual fatty acids (pentadecanoic acid, oleic acid, palmitic acid and linoleic acid acid) were tested at final concentrations in the wells of 0.0028, 0.0049, 0.038, 0.049, 0.38 and 0.49 M. For the combined fatty acids, pentadecanoic acid (at -46 % by content) was used as the reference compound and combined with oleic acid, palmitic acid and linoleic acid (i.e pentadecanoic acid: oleic acid: palmitic acid: linoleic acid at ratio of 12:5:4:1 ).
2.2 Anti-inflammatory assays
Ethical approval (003/09/Animal) from the University of KwaZulu-Natal Animal Ethics Subcommittee was obtained prior to the investigation of croton oil-induced oedema in a mouse model. Guidelines by the University of KwaZulu-Natal Animal Ethics Subcommittee and Biomedical Resource Unit for the maintenance and treatment of laboratory animals were followed. Young adult Balb/c mice weighing 29-32 g were obtained from the Biomedical Resource Unit of the University of KwaZulu-Natal. The mice were maintained under controlled laboratory conditions with free access to food and water and with a normal day/night cycle.
For the topical anti-inflammatory assays, the study design of Lopez and co-workers (Lopez A., Sims DE., Ablett RF., Skinner RE., Leger LW., Lariviere CM., Jamieson LA., Martinez- Burnes J., Zawadzka GG. (1999). Effect of emu oil on auricular inflammation induced with croton oil in mice. American Journal of Veterinary Resonance, 60: 1558-1561 ) was essentially followed, but with modifications. For the oral anti-inflammatory assays, the study designs of Ghannadi and co-workers (Ghannadi A., Hajhashemi V., Jafarabadi H. (2005). An investigation of the analgesic and anti-inflammatory effects of Nigella sativa seed polyphenols. Journal of Medicinal Food, 8:488-493) and that of Hong and co-workers (Hong M., Zhong S., Bian R. (2001 ). Tortoise oil, turtle oil, compositions containing them, their preparation processed and uses. United States Patent 6,296,979 B1 ) were implemented, but with modifications. Equal volumes of croton oil were mixed with acetone as vehicle and applied (50 μΙ; 1 hour) onto the inner surface of the right auricle or each mouse to induce oedema. The right auricle of each mouse was treated and the left auricle was used as the negative control and was left untreated. Diclofenac (0.07 mg; 3 hours) and fatty acids (0.23
mg pentadecanoic acid; 0.081 mg palmitic acid; 0.1 1 1 mg oleic acid and 0.0225 mg linoleic acid) in combination with quercetin (0.5 mg) was topically administered in 50 μΙ acetone and the mice treated for 3 to 6 hours. The combination of fatty acids corresponds with the ratio in which they were naturally found in the Nile crocodile oil. Acetone as a vehicle has not been documented to have an anti-inflammatory effect on its own. Mice were euthanized in a CO2 chamber after treatment for 3 to 6 hours. From each mouse, left and right auricle biopsy specimens were obtained with a 6 mm biopsy punch and then weighed on an analytical balance. 2.3 Data analysis
Data are reported as the mean ± standard error of the mean of at least four to five independent experiments with duplicate measurements. For the antimicrobial assays, microbial growth was quantified as a percentage of the control without any test compound. For the anti-inflammatory assays, oedema was quantified by calculating the difference in weights of the right and left auricle biopsy specimens and expressed as a percentage of the croton oil control. Statistical comparisons were made by one-way ANOVA followed by Bonferroni's post-test for multiple comparisons, or by Student's two-tailed paired f-test to determine P values. A value of P < 0.05 was considered significant.
3. Results
3.1 Microbial Susceptibility
Fatty acids have been previously documented to possess antimicrobial activity against a variety of pathogenic microorganisms. The relatively high concentrations of linoleic acid and oleic acid may be responsible for the antimicrobial activity of crocodile oil. The antimicrobial activity of the four fatty acids (pentadecanoic acid, oleic acid, palmitic acid and linoleic acid acid) found in crocodile oil were assessed against Staphylococcus aureus, Klebsiella pneumonia and Candida albicans, however, the pentadecanoic acid content of the fatty acid composition was increased from that found in nature in crocodile fat and oil.
The antimicrobial activities of the combination are depicted in Figure 1 . Interestingly, the activity was not potentiated but rather antagonised at the higher concentration range from 0.39 M onwards against all three species. This could be due to the lower solubility of the fatty acids at higher concentrations and support the comments of Kabara and co-workers (Kabara JJ., Swieczkowski DM., Conley AJ., Truant J. P. (1972). Fatty acids and derivatives
as antimicrobial agents. Antimicrobial Agents and Chemotherapy, 2:23-28.) that it is considerably difficult to test lipids due to their insolubility.
Figure 1. Microbial susceptibility to combination fatty acids. The percentage growth of S. aureus (A), K. pneumonia (B) and C. albicans (C) was measured against increasing concentrations of a mixture of pentadecanoic acid, oleic acid, palmitic acid and linoleic acid in the ratio 12:5:4:1 . The concentration (M) of the reference fatty acid, pentadecanoic acid, is indicated in each figure. Data are the mean ± standard error of the mean of duplicate measurements from 4 independent experiments. Statistical comparisons of activity were by one-way ANOVA followed by Bonferroni's post-test; **, P < 0.01 ; ***, P < 0.001 versus no fatty acid combination control.
3.2 Anti-inflammatory activity It has been previously documented that linoleic acid reduced oedema in a mouse model of acute auricular inflammation, and that the anti-inflammatory activity was due to the inhibition of the production of pro-inflammatory eicosanoids from arachidonic acid (Dobner MJ., Sosa S., Schwaiger S., Altinier G., Delia Loggia R., Kaneider NC, Stuppner H. (2004). Antiinflammatory activity of Leontopodium alpinum and its constituents. Planta Medica, 70:502- 508). The relatively high concentrations of linoleic acid may therefore be responsible for the anti-inflammatory activity of crocodile oil. Thus, the topical anti-inflammatory activities of the combined fatty acids in which the pentadecanoic acid content had been increased beyond the ratio naturally found in crocodile oil were tested in a mouse model of acute auricular contact dermatitis and the results are depicted in Figure 2.
Figure 2. The topical anti-inflammatory activity of fatty acids in combination with quercetin. Activity was measured in a mouse model of acute contact dermatitis. Diclofenac (0.07 mg; 3 hours) and fatty acids (0.23 mg pentadecanoic acid; 0.081 mg palmitic acid; 0.1 1 1 mg oleic acid and 0.0225 mg linoleic acid acid) in combination with quercetin (0.5 mg) was topically administered in 50 μΙ acetone and the mice treated for 3 to 6 hours. After treatment, the reduction in swelling of the auricular biopsies was determined and the change in weight was expressed as a percentage. Data represents the mean ± standard error of the mean of duplicate measurements from at least 4 independent experiments. Statistical comparisons of activity were by one-way ANOVA followed by Bonferroni's post-test or by Student's two- tailed paired f-test to determine P values.: P < 0.001 versus croton oil only control; ###, P < 0.001 versus diclofenac. It was previously determined that 0.07 mg diclofenac for 3 hours treatment exhibited the optimal effect.
4. Discussion
From the results above it is evident that fatty acids in this combination that are not found in nature exhibit significant antimicrobial and anti-inflammatory activities. The combination of fatty acids with quercetin showed a tendency to further increase anti-inflammatory activity, suggesting potentiation. This anti-inflammatory activity was significantly more pronounced that that of the optimal dose of diclofenac. Many microbial infections are commonly associated with inflammation and therefore this combination may be useful as a substitute for a topically applied corticosteroid.
The inventors this believe that the invention has benefits and advantages in the treatment of microbial infections and inflammatory conditions.
Claims
1 . A fatty acid composition including the constituent fatty acids pentadecanoic acid, oleic acid, palmitic acid and linoleic acid in a ration other than what is that commonly found in nature.
A fatty acid composition as claimed in claim 1 , wherein the constituent amount of the pentadecanoic acid in the composition ranges from 25 mol% to 66 mol%.
A fatty acid composition as claimed in claim 2 wherein the constituent amount of the pentadecanoic acid ranges from 30 mol% to 55 mol%.
A fatty acid composition as claimed in any one of the preceding claims, wherein the constituent amount of the linoleic acid in the composition ranges from 1 mol% to 10 mol%.
A fatty acid composition as claimed in claim 4, wherein the constituent amount of the linoleic acid ranges from 3 mol% to 7 mol%.
6. A fatty acid composition as claimed in any one of the preceding claims, wherein the constituent amount of the oleic acid in the composition ranges from 10 mol% to 40 mol%.
7. A fatty acid composition as claimed in 6, wherein the constituent amount of the oleic acid in the composition ranges from 16 mol% to 30 mol%.
8. A fatty acid composition as claimed in any one of the preceding claims, wherein the constituent amount of the palmitic acid in the composition ranges from 12 mol% to 36 mol%.
9. A fatty acid composition as claimed in claim 8, wherein the constituent amount of the palmitic acid in the composition ranges from 12 mol% to 25 mol%.
10. A fatty acid composition as claimed in any one of the preceding claims, wherein the constituent amount of the pentadecanoic acid is 46 mol%, the linoleic acid is 4.5 mol%, the oleic is 22 mol% and the palmitic acid is 18 mol%.
1 1 . A fatty acid composition as claimed in claim 1 , wherein the constituent amount of the linoleic acid in the composition is lower than the constituent amounts of any one of the other three fatty acid constituents.
12. A fatty acid composition as claimed in claim 1 , wherein the constituent amount pentadecanoic acid is the highest constituent amount in the composition.
13. A fatty acid composition as claimed in any one of the preceding claims, wherein the constituents of the composition are derived from nature or are synthetic.
14. A fatty acid composition as claimed in any one of the preceding claims, wherein the fatty acids are reptilian in origin.
15. A fatty acid composition as claimed in claim 14, wherein the reptiles are from the family Crocodylidae and/or Alligato dae.
16. A fatty acid composition as claimed in claim 1 , wherein the ratio of pentadecanoic acid: oleic acid: palmitic acid: linoleic acid is 12:5:4:1 .
17. The use of a fatty acid composition including at least pentadecanoic acid, oleic acid, palmitic acid and linoleic acid acids substantially as described above, in preparation of an antimicrobial medicament by the administration of the medicament at a desired dosage.
18. The use of a fatty acid composition including at least pentadecanoic acid, oleic acid, palmitic acid and linoleic acid acids substantially as described above, in the preparation of an inflammatory medicament by administration of the medicament at a desired dosage.
19. An anti-inflammatory composition as claimed in claim 18, wherein the composition includes pentadecanoic acid, oleic acid, palmitic acid, linoleic acid acids and a flavonoid- type substance.
20. An anti-inflammatory composition as claimed in claim 19, wherein the flavonoid-type substance is any one or more of the group including quercetin, an analogue and/or an equivalent thereof.
An anti-inflammatory composition as claimed in any one of claims 19 to 20 wherein the ratio of the flavonoid-type substance to the total of the fatty acid constituent is greater than 1 :1 .
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA2014/00497 | 2014-01-22 | ||
| ZA201400497 | 2014-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015110977A1 true WO2015110977A1 (en) | 2015-07-30 |
Family
ID=53680897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2015/050484 Ceased WO2015110977A1 (en) | 2014-01-22 | 2015-01-22 | Fatty acid composition and medicinal use thereof |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2015110977A1 (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018122409A1 (en) * | 2016-12-29 | 2018-07-05 | The United States Of America As Represented By The Secretary Of The Navy | Compositions comprising fatty acids for the treatment of inflammation |
| WO2019052629A1 (en) * | 2017-09-12 | 2019-03-21 | Sunregen Healthcare Ag | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
| CN111394189A (en) * | 2020-04-23 | 2020-07-10 | 朱修建 | Production process of crocodile essential oil |
| US10792266B2 (en) | 2017-10-23 | 2020-10-06 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome |
| WO2022118183A1 (en) * | 2020-12-01 | 2022-06-09 | Bionexa S.R.L | Senotherapeutic substance |
| US11406616B2 (en) | 2016-06-08 | 2022-08-09 | Sunregen Healthcare Ag | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
| US11992473B2 (en) | 2018-05-23 | 2024-05-28 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity |
| US12059400B2 (en) | 2017-07-05 | 2024-08-13 | Vera Salus Ricerca S.R.L. | Medical compound |
| WO2025081715A1 (en) * | 2023-10-20 | 2025-04-24 | 中国农业大学 | Use of pentadecanoic acid in relieving weaning stress of animals |
| US12370166B2 (en) | 2021-11-03 | 2025-07-29 | Epitracker, Inc. | Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity |
| US12427179B2 (en) | 2019-01-09 | 2025-09-30 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of neurodegenerative diseases |
| US12440473B2 (en) | 2019-03-04 | 2025-10-14 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011031166A2 (en) * | 2009-09-14 | 2011-03-17 | Ewos Innovation As | Feed composition |
| CN101991530A (en) * | 2009-08-28 | 2011-03-30 | 沈阳志鹰制药厂 | Vinpocetine containing high-capacity sodium chloride injection and preparation method thereof |
| US20110077301A1 (en) * | 2008-05-30 | 2011-03-31 | Ceva Sante Animale Sa | Novel methods of administering a mixture of fatty acids for the treatment of non-human mammals |
-
2015
- 2015-01-22 WO PCT/IB2015/050484 patent/WO2015110977A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110077301A1 (en) * | 2008-05-30 | 2011-03-31 | Ceva Sante Animale Sa | Novel methods of administering a mixture of fatty acids for the treatment of non-human mammals |
| CN101991530A (en) * | 2009-08-28 | 2011-03-30 | 沈阳志鹰制药厂 | Vinpocetine containing high-capacity sodium chloride injection and preparation method thereof |
| WO2011031166A2 (en) * | 2009-09-14 | 2011-03-17 | Ewos Innovation As | Feed composition |
Non-Patent Citations (4)
| Title |
|---|
| BUTHELEZI, S. ET AL.: "An investigation of the antimicrobial and anti-inflammatory activities of crocodile oil", JOURNAL OF ETHNOPHARMACOLOGY, vol. 143, 2012, pages 325 - 330, XP055214795 * |
| DATABASE WPI Derwent World Patents Index; * |
| MATHEW, M. ET AL.: "Analgesic and Anti-inflammatory Activities of Liver Oils of Four Shark Species from Indian EEZ", JOURNAL OF FOOD LIPIDS, vol. 15, 2008, pages 470 - 487, XP055214802 * |
| STATON, M. A. ET AL.: "Essential Fatty Acid Nutrition of the American Alligator (Alligator mississippiensis", J. NUTR., vol. 120, no. 7, 1990, pages 674 - 685 * |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11406616B2 (en) | 2016-06-08 | 2022-08-09 | Sunregen Healthcare Ag | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
| EP4234038A3 (en) * | 2016-12-29 | 2023-09-20 | The United States Of America As Represented By The Secretary Of The Navy | Compositions comprising heptadecanoic acid for the treatment of inflammation and related conditions |
| JP2018127444A (en) * | 2016-12-29 | 2018-08-16 | ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ、アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ ネイビーＧｏｖｅｒｎｍｅｎｔ Ｏｆ Ｔｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ Ｏｆ Ａｍｅｒｉｃａ， Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｔｈｅ Ｎａｖｙ | Compositions and methods for diagnosis and treatment of inflammation |
| JP7678024B2 (en) | 2016-12-29 | 2025-05-15 | ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ、アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ ネイビー | Compositions and methods for the diagnosis and treatment of inflammation |
| WO2018122409A1 (en) * | 2016-12-29 | 2018-07-05 | The United States Of America As Represented By The Secretary Of The Navy | Compositions comprising fatty acids for the treatment of inflammation |
| JP7266366B2 (en) | 2016-12-29 | 2023-04-28 | ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ、アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ ネイビー | Compositions and methods for diagnosis and treatment of inflammation |
| JP2023099029A (en) * | 2016-12-29 | 2023-07-11 | ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ、アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ ネイビー | Compositions and methods for diagnosis and treatment of inflammation |
| US12059400B2 (en) | 2017-07-05 | 2024-08-13 | Vera Salus Ricerca S.R.L. | Medical compound |
| WO2019052629A1 (en) * | 2017-09-12 | 2019-03-21 | Sunregen Healthcare Ag | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
| US10792266B2 (en) | 2017-10-23 | 2020-10-06 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome |
| US11951088B2 (en) | 2017-10-23 | 2024-04-09 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome |
| US11992473B2 (en) | 2018-05-23 | 2024-05-28 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity |
| US12427179B2 (en) | 2019-01-09 | 2025-09-30 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of neurodegenerative diseases |
| US12440473B2 (en) | 2019-03-04 | 2025-10-14 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain |
| CN111394189A (en) * | 2020-04-23 | 2020-07-10 | 朱修建 | Production process of crocodile essential oil |
| CN116744916A (en) * | 2020-12-01 | 2023-09-12 | 拜奥拿萨有限责任公司 | anti-aging treatment substances |
| WO2022118183A1 (en) * | 2020-12-01 | 2022-06-09 | Bionexa S.R.L | Senotherapeutic substance |
| US12370166B2 (en) | 2021-11-03 | 2025-07-29 | Epitracker, Inc. | Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity |
| WO2025081715A1 (en) * | 2023-10-20 | 2025-04-24 | 中国农业大学 | Use of pentadecanoic acid in relieving weaning stress of animals |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015110977A1 (en) | Fatty acid composition and medicinal use thereof | |
| Ahn et al. | Gallic acid-g-chitosan modulates inflammatory responses in LPS-stimulated RAW264. 7 cells via NF-κB, AP-1, and MAPK pathways | |
| Noori et al. | Synergistic effects of honey and propolis toward drug multi-resistant Staphylococcus aureus, Escherichia coli and Candida albicans isolates in single and polymicrobial cultures | |
| Yan et al. | The effect of emodin on Staphylococcus aureus strains in planktonic form and biofilm formation in vitro | |
| Vignisse et al. | Thiamine and benfotiamine prevent stress-induced suppression of hippocampal neurogenesis in mice exposed to predation without affecting brain thiamine diphosphate levels | |
| Feng et al. | Lycopene suppresses LPS-induced NO and IL-6 production by inhibiting the activation of ERK, p38MAPK, and NF-κB in macrophages | |
| Zheng et al. | Anti-inflammatory effects of catechols in lipopolysaccharide-stimulated microglia cells: inhibition of microglial neurotoxicity | |
| Hirao et al. | Tea catechins reduce inflammatory reactions via mitogen-activated protein kinase pathways in toll-like receptor 2 ligand-stimulated dental pulp cells | |
| Wang et al. | Gastrodin ameliorates depression-like behaviors and up-regulates proliferation of hippocampal-derived neural stem cells in rats: involvement of its anti-inflammatory action | |
| Wang et al. | Screening of condensed tannins from Canadian prairie forages for anti–Escherichia coli O157: H7 with an emphasis on purple prairie clover (Dalea purpurea Vent) | |
| KANDUJA et al. | Resveratrol inhibits N-nitrosodiethylamine-induced ornithine decarboxylase and cyclooxygenase in mice | |
| Chen et al. | Anti-inflammatory effects of chicanine on murine macrophage by down-regulating LPS-induced inflammatory cytokines in IκBα/MAPK/ERK signaling pathways | |
| Huang et al. | Interaction of inflammatory and anti-inflammatory responses in microglia by Staphylococcus aureus-derived lipoteichoic acid | |
| Zou et al. | Synergistic effect of xylitol and ursolic acid combination on oral biofilms | |
| Alaba et al. | 15–Lipoxygenase inhibition of Commelina benghalensis, Tradescantia fluminensis, Tradescantia zebrina | |
| KR101161479B1 (en) | Pharmaceutical composition comprising chaff vinegar for preventing or treating inflammatory disease | |
| Srisook et al. | Anti-inflammatory effect of trans-4-methoxycinnamaldehyde from Etlingera pavieana in LPS-stimulated macrophages mediated through inactivation of NF-κB and JNK/c-Jun signaling pathways and in rat models of acute inflammation | |
| Khotimchenko et al. | Marine natural products from the Russian Pacific as sources of drugs for neurodegenerative diseases | |
| Park et al. | Schisandra chinensis α-iso-cubebenol induces heme oxygenase-1 expression through PI3K/Akt and Nrf2 signaling and has anti-inflammatory activity in Porphyromonas gingivalis lipopolysaccharide-stimulated macrophages | |
| Yang et al. | Spinosad induces autophagy of Spodoptera frugiperda Sf9 cells and the activation of AMPK/mTOR signaling pathway | |
| Mirkarimi et al. | The antimicrobial activity of grape seed extract against two important oral pathogens | |
| Park et al. | Anti-inflammatory effects of novel polygonum multiflorum compound via inhibiting NF-κB/MAPK and upregulating the Nrf2 pathways in LPS-stimulated microglia | |
| Goc et al. | Anti-borreliae efficacy of selected organic oils and fatty acids | |
| Kovacik et al. | In vitro assessment of gentamicin cytotoxicity on the selected mammalian cell line (Vero cells) | |
| Ma et al. | Torreya grandis oil attenuates cognitive impairment in scopolamine-induced mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15740642 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22/12/2016) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15740642 Country of ref document: EP Kind code of ref document: A1 |